Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 13/2005

01.09.2005 | Review Article

Autoimmune Bullous Diseases

Ocular Manifestations and Management

verfasst von: Dr Caroline Laforest, Shyamala C. Huilgol, Robert Casson, Dinesh Selva, Igal Leibovitch

Erschienen in: Drugs | Ausgabe 13/2005

Einloggen, um Zugang zu erhalten

Abstract

The ocular manifestations of autoimmune bullous diseases are common and potentially sight-threatening. Major ophthalmic involvement is most commonly seen in mucous membrane pemphigoid (cicatricial pemphigoid), epidermolysis bullosa acquisita, linear IgA bullous disease, pemphigus vulgaris and paraneo-plastic pemphigus. The main pathological process is related to autoimmune-induced onjunctival inflammation with consequent lid and corneal pathology, which may eventually result in permanent visual loss. Ocular involvement can be asymptomatic. Early detection is aided by careful attention to symptoms and signs of early ophthalmic disease. Ocular disease can be difficult to treat and management usually involves systemic therapy with immunomodulators to control inflammation and prevent progression to irreversible blindness, as well as surgical intervention in advanced disease. Recent advances in treatment, including methotrexate, mycophenolate mofetil, monoclonal antibodies and topical tacrolimus therapies, have led to promising results.
Literatur
1.
Camisa C, Meisler DM. Immunobullous diseases with ocular involvement. Dermatol Clin 1992; 10: 555–70PubMed
2.
Baer JC, Hemady RK. Ocular manifestations of systemic immune disease. In: Bosniak S, editor. Principles and practice of ophthalmic plastic and reconstructive surgery. Vol. 1. Philadelphia (PA): WB Saunders Company, 1996: 94–119
3.
Lifshitz T, Levy J, Cagnano E, et al. Severe conjunctival and eyelid involvement in pemphigus vulgaris. Int Ophthalmol 2004; 25: 73–4PubMedCrossRef
4.
Venning VA, Frith PA, Bron AJ, et al. Mucosal involvement in bullous and cicatricial pemphigoid: a clinical and immunopathological study. Br J Dermatol 1988; 118: 7–15PubMedCrossRef
5.
Korman NJ. New immunomodulating drugs in autoimmune blistering disease. Dermatol Clin 2001; 19: 637–48PubMedCrossRef
6.
Mondino BJ. Cicatricial pemphigoid and erythema multiforme. Ophthalmology 1990; 97: 939–52PubMed
7.
Huilgol SC, Black MM. Management of the immunobullous disorders: 1. Pemphigoid. Clin Exp Dermatol 1995; 20: 189–201CrossRef
8.
Ahmed M, Ghassan Z, Khawaja F, et al. Ocular cicatricial pemphigoid: pathogenesis, diagnosis and treatment. Prog Retin Eye Res 2004; 23: 579–92PubMedCrossRef
9.
Jackson WB, Gilmore NJ. Ocular immunology: a review (second of two parts). Can J Ophthalmol 1981; 16: 59–64PubMed
10.
Elder MJ, Lightman S. The immunological features and pathophysiology of ocular cicatricial pemphigoid. Eye 1994; 8: 196–9PubMedCrossRef
11.
Razzaque MS, Foster CS, Ahmed AR. Tissue and molecular events in human conjunctival scarring in ocular cicatricial pemphigoid. Histol Histopathol 2001; 16: 1203–12PubMed
12.
Kanski JJ. Disorders of the conjunctiva. In: Kanski JJ, editor. Clinical ophthalmology. 4th ed. Oxford: Butterworth Heinemann, 1999: 71–82
13.
Foster CS. Cicatricial pemphigoid. Trans Am Ophthalmol Soc 1986; 84: 527–663PubMed
14.
15.
Bernauer W, Broadway DC, Wright P. Chronic progressive conjunctival cicatrisation. Eye 1993; 7: 371–8PubMedCrossRef
16.
Hodak E, Kremer I, David M, et al. Conjunctival involvement in pemphigus vulgaris: a clinical, histopathological and immunofluorescence study. Br J Dermatol 1990; 123: 615–20PubMedCrossRef
17.
Becker BA, Gaspari AA. Pemphigus vulgaris and vegetans. Dermatol Clin 1993; 11: 429–52PubMed
18.
Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138: 370–9PubMedCrossRef
19.
20.
Leonard JN, Wright P, Williams DM, et al. The relationship between linear IgA disease and benign mucous membrane pemphigoid. Br J Dermatol 1984; 110: 307–14PubMedCrossRef
21.
Ahmed AR, Kurgis BS, Rogers III RS. Cicatricial pemphigoid. J Am Acad Dermatol 1991; 24: 987–1001PubMedCrossRef
22.
23.
Lever WF. Pemphigus and pemphigoid: a review of the advances made since 1964. J Am Acad Dermatol 1979; 1: 2–31PubMedCrossRef
24.
Hardy KM, Perry HO, Pingree GC, et al. Benign mucous membrane pemphigoid. Arch Dermatol 1971; 104: 467–75PubMedCrossRef
25.
Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Opthalmology 2004; 111: 45–52CrossRef
26.
Mondino BJ, Brown SI. Ocular cicatricial pemphigoid. Ophthalmology 1981 Feb; 88(2): 95–100PubMed
27.
Fleming JC, Cape RC. Surgical intervention in conjunction with medical treatment of cicaticial pemphigoid. In: Bosniak S, editor. Principles and practice of ophthalmic plastic and reconstructive surgery. Vol. 1. Philadelphia (PA): WB Saunders Company, 1996: 196–202
28.
Foster CS, Wilson LA, Ekins MB. Immunosuppressive therapy for progressive cicatricial pemphigoid. Ophthalmology 1982; 89: 340–53PubMed
29.
Mondino BJ, Brown SI. Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol 1983 Oct; 96(4): 453–9PubMed
30.
Smith RJ, Manche EE, Mondino BJ. Ocular cicatricial pemphigoid and ocular manifestations of pemphigus vulgaris. Int Ophthalmol Clin 1997; 37: 63–75PubMedCrossRef
31.
Faraj HG, Hoang-Xuan T. Chronic cicatrising conjunctivits. Curr Opin Ophthalmol 2001; 12: 250–7PubMedCrossRef
32.
Neumann R, Tauber J, Foster CS. Remission and recurrence after withdrawal of therapy for ocular cicatricial pemphigoid. Ophthalmology 1991; 98: 858–62PubMed
33.
Yeh SW, Ahmed B, Sami N, et al. Blistering disorders: diagnosis and treatment. Dermatol Ther 2003; 16: 214–23PubMedCrossRef
34.
Hochman MA, Mayers M. Epidermolysis bullosa, staphylococcal scalded skin syndrome, dermatitis herpetiformis. Int Ophthalmol Clin 1997; 37: 77–92PubMedCrossRef
35.
36.
Weinberg MA, Insler MS, Campen RB. Mucocutaneous features of autoimmune blistering diseases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1997; 84: 517–34PubMedCrossRef
37.
Luke MC, Darling TN, Hsu R, et al. Mucosal morbidity in patients with epidermolysis bullosa equisita. Arch Dermatol 1999; 135: 954–9PubMedCrossRef
38.
Dantas PE, Nishiwaki-Dantas MC, Segium MH, et al. Bilateral corneal involvement in epidermolysis bullosa acquisita. Cornea 2001; 20: 664–7PubMedCrossRef
39.
Lang Jr PG, Tapert MJ. Severe ocular involvement in a patient with epidermolysis bullosa acquisita. J Am Acad Dermatol 1987; 16: 439–43PubMedCrossRef
40.
Bauer JW, Schaeppi H, Metze D, et al. Ocular involvement in IgA-epidermolysis bullosa acquisita. Br J Dermatol 1999; 141: 887–92PubMedCrossRef
41.
Leonard JN, Haffenden GP, Ring NP, et al. Linear IgA disease in adults. Br J Dermatol 1982; 107: 301–16PubMedCrossRef
42.
Kelly SE, Frith PA, Millard PR, et al. A clinicopathological study of mucosal involvement in linear IgA disease. Br J Dermatol 1988; 119: 161–70PubMedCrossRef
43.
Leonard JN, Wright P, Williams DM, et al. Skin diseases and the dry eye. Trans Ophthalmol Soc U K 1985; 104: 467–76PubMed
44.
45.
Letko E, Bhol K, Foster CS, et al. Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy. Ophthalmology 2000; 107: 1524–8PubMedCrossRef
46.
Huilgol SC, Black MM. Management of the immunobullous disorders II Pemphigus. Clin Exp Dermatol 1995; 20: 283–93PubMedCrossRef
47.
Baykal HE, Pleyer U, Sonnichsen K, et al. Severe eye involvement in pemphigus vulgaris. Ophthalmologe 1995; 92: 854–7PubMed
48.
49.
Bean SF, Holubar K, Gillett RB. Pemphigus involving the eyes. Arch Dermatol 1975; 111: 1484–6PubMedCrossRef
50.
Nguyen V, Ndoye A, Bassler K, et al. Classification, clinical manifestations, and immunopathological mechanisms of the epithelial variant of paraneoplastic autoimmune multiorgan syndrome. Arch Dermatol 2001; 137: 193–206PubMed
51.
Sugar A. Paraneoplastic pemphigus and ophthalmology. Ophthalmology 1992; 99: 5–6PubMed
52.
Lam S, Stone MS, Goeken JA. Paraneoplastic pemphigus, cicatricial conjunctivitis, and acanthosis nigricans with pachydermatoglyphy in a patient with bronchogenic squamous cell carcinoma. Ophthalmology 1992; 99: 108–13PubMed
53.
Hoohwy T, Bang K, Steiniche T, et al. Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and lymphocytic leukaemia. Eur J Haematol 2004; 73: 206–9CrossRef
54.
Meyers SJ, Varley GA, Meisler DM, et al. Conjunctival involvement in paraneoplastic pemphigus. Am J Ophthalmol 1992; 114: 621–4PubMed
55.
Sklavourou A, Laskaris G. Paraneoplastic pemphigus: a review. Oral Oncol 1998; 34: 437–40CrossRef
56.
Anhalt GJ, Kim S, Stanley JR, et al. Paraneoplastic pemphigus: an autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323: 1729–35PubMedCrossRef
57.
Beele H, Claerhout I, Kestelyn P, et al. Bilateral corneal melting in a patient with paraneoplastic pemphigus. Dermatology 2001; 202: 147–50PubMedCrossRef
58.
Elder MJ, Bernauer W, Leonard J, et al. Progression of disease in ocular cicatricial pemphigoid. Br J Ophthalmol 1996; 80: 292–6PubMedCrossRef
59.
Fern AI, Jay JL, Young H, et al. Dapsone therapy for the acute inflammatory phase of ocular pemphigoid. Br J Ophthalmol 1992; 76: 332–3PubMedCrossRef
60.
Kirtschig G, Murreil D, Wojnarowska F, et al. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita: a systematic literature review. Arch Dermatol 2002; 138: 380–4PubMedCrossRef
61.
Elder MJ, Lightman S, Dart JK. Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid. Br J Ophthalmol 1995; 79: 264–6PubMedCrossRef
62.
Foster CS, Ahmed AR. Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid. Ophthalmology 1999; 106: 2136–43PubMedCrossRef
63.
McCluskey P, Chang JH, Singh R, et al. Methotrexate therapy for ocular cicatricial pemphigoid. Ophthalmology 2004; 111: 796–801PubMedCrossRef
64.
Shah SS, Lowder CY, Schmitt MA, et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology 1992; 99: 1419–23PubMed
65.
66.
Assman T, Ruzicka T. New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications. Clin Dermatol 2002; 20: 505–14CrossRef
67.
Ingen-Housz-Oro S, Prost-Squarcioni C, Pascal F, et al. Cicatricial pemphigoid: treatment with mycophenolate mofetil. Ann Dermatol Venereol 2005; 132: 13–6PubMedCrossRef
68.
Foster CS, Sainz de la Maza M. Ocular cicatricial pemphigoid review. Curr Opin Allergy Clin Immunol 2004; 4: 435–9PubMedCrossRef
69.
Megahed M, Schmiedberg S, Becker J, et al. Treatment of cicatricial pemphigoid with mycophenolate mofetil as a steroid sparing agent. J Am Acad Dermatol 2001; 45: 256–9PubMedCrossRef
70.
Jolles S. High dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders. Clin Exp Immunol 2002; 129: 385–9PubMedCrossRef
71.
Miserocchi E, Baltatzis S, Roque MR, et al. The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid. Ophthalmology 2002; 109: 111–8PubMedCrossRef
72.
Donnenfeld ED, Perry HD, Wallerstein A, et al. Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid. Opthalmology 1999; 106: 72–8CrossRef
73.
Secchi AAG, Tognon MS. Intraoperative mitomycin C in the treatment of cicatricial obliterations of conjunctival fornices. Am J Ophthamol 1996; 122: 728–30
74.
Celis J, Lopez N, Garcia M, et al. Subconjunctival mitomycin for the treatment of ocular cicatricial pemphigoid. Arch Soc Esp Oftalmol 2002; 77: 501–6
75.
Hall VC, Liesegang TJ, Kostick DA, et al. Ocular mucous membrane pemphigoid and ocular pemphigus vulgaris treated topically with tacrolimus ointment. Arch Dermatol 2003; 139: 1083–4PubMedCrossRef
76.
Papaliodis GN, Chu D, Foster CS. Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2004; 111: 45–52CrossRef
77.
Vodegel RM, de Jong MC, Pas HH, et al. IgA-mediated epidermolysis bullosa acquisita: two cases and a review of the literature. J Am Acad Dermatol 2002; 47: 919–25PubMedCrossRef
78.
Gordon KB, Chan LS, Woodley DT. Treatment of refractory epidermolysis bullosa acquisita with extracorporeal photochemotherapy. Br J Dermatol 1997; 136: 415–20PubMedCrossRef
79.
Trebing D, Ziemar A. Acquired epidermolysa bullosa with a highly varied clinical picture and successful treatment with mycophenolate mofetil. Hautarzt 2001; 52: 717–21PubMedCrossRef
80.
Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999; 140: 865–74PubMedCrossRef
81.
Khan IU, Bhol KC, Ahmed AR. Linear IgA bullous dermatosis in patients with chronic renal failure: a response to IVIg. J Am Acad Dermatol 1999; 40: 485–8PubMedCrossRef
82.
Olsen KE, Holland EJ. The association between ocular cicatricial pemphigoid and rheumatoid arthritis. Cornea 1998; 17: 504–7PubMedCrossRef
83.
Aberer W, Wolff-Schreiner EC, Stingl G, et al. Azathioprine in the treatment of pemphigus vulgaris. J Am Acad Dermatol 1987; 16: 527–33PubMedCrossRef
84.
Enk AH, Knop J. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 1997; 350: 494PubMedCrossRef
85.
Ho VC, Zloty DM. Immunosuppressive agents in dermatology. Dermatol Ther 1993; 11: 73–85
86.
Grundmann-Kollmann M, Kaskel P, Leiter U, et al. Treatment of pemphigus vulgaris and bullous pemphigoid with mycophenolate mofetil monotherapy. Arch Dermatol 1999 Jun; 135(6): 724–5PubMedCrossRef
87.
Pasricha JS, Thanzama J, Khan UK. Intermittent high dose dexamethasone-cyclophosphamide therapy for pemphigus. Br J Dermatol 1988; 119: 73–7PubMedCrossRef
88.
Williams JV, Marks Jr JG, Billingsley EM. Use of mycophenolate mofetil in the treatment of paraneoplastic pemphigus. Br J Dermatol 2000; 142: 506–8PubMedCrossRef
89.
Choo PH. Distichiasis, trichiasis and entropion: advances in management. Int Ophthalmol Clin 2002; 42: 75–87PubMedCrossRef
90.
Elder MJ, Collin R. Lid surgery: the management of cicatricial entropion and trichiasis. Dev Ophthalmol 1997; 28: 207–18PubMedCrossRef
91.
Davies RP. Surgical options for eyelid problems. Aust Fam Physician 2002; 31: 239–45PubMed
92.
Elder MJ, Bernauer W. Cryotherapy for trichiasis in ocular cicatricial pemphigoid. Br J Ophthalmol 1994; 78: 769–71PubMedCrossRef
93.
Elder MJ, Dart JK, Collin R. Inferior retractor plication surgery for lower lid entropion with trichiasis in ocular cicatricial pemphigoid. Br J Ophthalmol 1995; 79: 1003–6PubMedCrossRef
94.
Heilgenhaus A, Shore JW, Rubin PAD, et al. Long-term results of mucous membrane grafting in ocular cicatricial pemphigoid. Ophthalmology 1993; 100: 1283–8
95.
Park EH, Korn TS, Vasani SN, et al. Autologous allogeneic amniotic membrane grafting in Stevens-Johnson syndrome. Ophthal Plast Reconstr Surg 2003; 19: 250–1PubMedCrossRef
96.
Barabino S, Rolando M. Amniotic membrane transplantation elicits goblet cell repopulation after conjunctival reconstruction in the case of severe ocular cicatricial pemphigoid. Acta Ophthalmol Scand 2003; 81: 68–71PubMedCrossRef
97.
Honavar SG, Bansal AK, Sangwan VS, et al. Amniotic membrane transplantation for ocular surface reconstruction in Stevens-Johnson syndrome. Ophthalmology 2000; 107: 975–9PubMedCrossRef
98.
Tugal-Tutkin I, Akova YA, Foster CS. Penetrating keratoplasty in cicatrizing conjunctival diseases. Ophthalmology 1995; 102: 576–85
Metadaten
Titel
Autoimmune Bullous Diseases
Ocular Manifestations and Management
verfasst von
Dr Caroline Laforest
Shyamala C. Huilgol
Robert Casson
Dinesh Selva
Igal Leibovitch
Publikationsdatum
01.09.2005
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 13/2005
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200565130-00003

Weitere Artikel der Ausgabe 13/2005

Drugs 13/2005 Zur Ausgabe

Adis Drug Evaluation

Ramipril/Felodipine Extended-Release Fixed-Dose Combination

Adis Drug Evaluation

Trandolapril/Verapamil Sustained Release

Leading Article

Emerging Drug Targets for Antiretroviral Therapy

Adis Drug Evaluation

Bivalirudin

Adis Drug Evaluation

Sulfasalazine

Current Opinion

Medication Errors